Hims & Hers Health, Inc.
HIMSNYSEHealthcare · Services-Offices & Clinics of Doctors of Medicine · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $2.35B | $1.48B | $872.0M | $526.9M | $271.9M | $148.8M |
| Operating income | $105.6M | $61.9M | −$29.5M | −$68.7M | −$115.0M | −$15.1M |
| Net income | $128.4M | $126.0M | −$23.5M | −$65.7M | −$107.7M | −$18.1M |
| Total assets | $2.15B | $707.5M | $441.2M | $366.3M | $420.6M | $118.7M |
| Total liabilities | $1.61B | $230.8M | $97.2M | $54.6M | $86.0M | $15.6M |
| Equity | $540.9M | $476.7M | $344.0M | $311.7M | $334.6M | −$146.9M |
| EPS (diluted) | $0.51 | $0.53 | $-0.11 | $-0.32 | $-0.58 | $-0.51 |
| Shares out. | 258.2M | 236.8M | 209.3M | 204.5M | 186.8M | 35.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 4.5%
- Net margin
- 5.5%
- Return on equity
- 23.7%
- Return on assets
- 6.0%
- Return on capital (ROCE)
- 6.0%
- Liabilities / assets
- 74.9%
- Debt / equity
- 2.98×
- Book value / share
- $2.09
- Revenue growth (YoY)
- 59.0%
- Net income growth (YoY)
- 1.8%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 1.61grey zone
- Accruals / assets
- −8.0%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 warning● 5 good- High leverage (liabilities > 70% of assets)
- Altman Z″ in the grey zone
- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Susquehanna Securities, LlcPassive (13G)May 15, 2026
- Capital World InvestorsPassive (13G)May 14, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Jpmorgan Chase & CoPassive (13G)Mar 5, 2026
- Dudum AndrewActivist (13D)Aug 13, 2025
- Blackrock, Inc.Passive (13G)Apr 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Wells David BDirector | May 26, 2026 | Buy | 48,400 | $24.23 |
| Okupe OluyemiOfficer — Chief Financial Officer | May 18, 2026 | Option exercise | 7,950 | $5.01 |
| Boughton SoleilOfficer — Chief Legal Officer | Apr 20, 2026 | Sell | 9,463 | $30.00 |
| Okupe OluyemiOfficer — Chief Financial Officer | Apr 20, 2026 | Option exercise | 5,553 | $5.01 |
| Okupe OluyemiOfficer — Chief Financial Officer | Apr 16, 2026 | Sell | 36,922 | $25.90 |
| Dudum AndrewOfficer — Chief Executive Officer | Apr 9, 2026 | Gift | 422,933 | — |
| Okupe OluyemiOfficer — Chief Financial Officer | Apr 6, 2026 | Option exercise | 3,975 | $5.01 |
| Okupe OluyemiOfficer — Chief Financial Officer | Mar 20, 2026 | Option exercise | 4,489 | $5.01 |
| Becklund IreneOfficer — PAO | Mar 17, 2026 | Sell | 5,529 | $24.69 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 63.4M | 2.5 | +0.3% |
| Apr 30, 2026 | 63.2M | 1.5 | -9.5% |
| Apr 15, 2026 | 69.8M | 3.0 | -2.2% |
| Mar 31, 2026 | 71.4M | 2.5 | -14.3% |
| Mar 13, 2026 | 83.3M | 1.3 | -2.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · New financial obligation · Unregistered equity saleMay 21, 2026
- Other material eventMay 19, 2026
- Results of operationsMay 11, 2026
- Regulation FD disclosureMar 11, 2026
- Results of operationsFeb 23, 2026
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureFeb 19, 2026
- Other material eventNov 17, 2025
- Results of operationsNov 3, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.